MX2009006823A - Formas de dosificacion solidas de desintegracion oral que comprenden progestina y metodos para hacer y usar las mismas. - Google Patents

Formas de dosificacion solidas de desintegracion oral que comprenden progestina y metodos para hacer y usar las mismas.

Info

Publication number
MX2009006823A
MX2009006823A MX2009006823A MX2009006823A MX2009006823A MX 2009006823 A MX2009006823 A MX 2009006823A MX 2009006823 A MX2009006823 A MX 2009006823A MX 2009006823 A MX2009006823 A MX 2009006823A MX 2009006823 A MX2009006823 A MX 2009006823A
Authority
MX
Mexico
Prior art keywords
dosage forms
progestin
making
methods
orally disintegrating
Prior art date
Application number
MX2009006823A
Other languages
English (en)
Inventor
Tahseen A Chowdhury
Salah U Ahmed
Sundeep Sethia
Original Assignee
Duramed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duramed Pharmaceuticals Inc filed Critical Duramed Pharmaceuticals Inc
Publication of MX2009006823A publication Critical patent/MX2009006823A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se dirige a formas de dosificación farmacéuticas sólidas de desintegración oral, no efervescentes que comprenden progestina y métodos para hacer y usar las formas de dosificación para tratar afecciones en mujeres en necesidad de las mismas.
MX2009006823A 2006-12-20 2007-12-20 Formas de dosificacion solidas de desintegracion oral que comprenden progestina y metodos para hacer y usar las mismas. MX2009006823A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87582706P 2006-12-20 2006-12-20
PCT/US2007/025974 WO2008079245A2 (en) 2006-12-20 2007-12-20 Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof

Publications (1)

Publication Number Publication Date
MX2009006823A true MX2009006823A (es) 2009-07-03

Family

ID=39563076

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006823A MX2009006823A (es) 2006-12-20 2007-12-20 Formas de dosificacion solidas de desintegracion oral que comprenden progestina y metodos para hacer y usar las mismas.

Country Status (11)

Country Link
US (2) US7867515B2 (es)
EP (1) EP2124900B1 (es)
JP (1) JP5649305B2 (es)
AU (1) AU2007338843B2 (es)
BR (1) BRPI0719486A2 (es)
CA (1) CA2674776A1 (es)
ES (1) ES2531929T3 (es)
IL (1) IL199472A0 (es)
MX (1) MX2009006823A (es)
RU (1) RU2465907C2 (es)
WO (1) WO2008079245A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103054738A (zh) * 2006-02-14 2013-04-24 宝洁公司 包含响应性颗粒的个人护理组合物
ES2531929T3 (es) * 2006-12-20 2015-03-20 Teva Women's Health, Inc. Formas de dosificación solidas que se disgregan en la boca que comprenden progestina y métodos para hacer y usar las mismas
AU2008341138A1 (en) * 2007-12-20 2009-07-02 Teva Women's Health, Inc. Dosage regimens and pharmaceutical compositions and packages for emergency contraception
FR2937862B1 (fr) * 2008-11-03 2010-11-19 Mohammed Ridha Chakroun Kit contraceptif
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
WO2010119029A1 (en) 2009-04-14 2010-10-21 Laboratoire Hra-Pharma Method for on-demand contraception
JP6425540B2 (ja) 2011-06-01 2018-11-21 エステトラ エス．ペ．エール．エル． エステトロール中間体を製造するための方法
RS55293B1 (sr) 2011-06-01 2017-03-31 Estetra Sprl Postupak proizvodnje intermedijara estetrola
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
JP5928159B2 (ja) * 2012-05-28 2016-06-01 ニプロ株式会社 医薬組成物
FR2997627B1 (fr) 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
WO2015086643A1 (en) * 2013-12-12 2015-06-18 Donesta Bioscience B.V. Orally disintegrating solid dosage unit containing an estetrol component
CN103877048A (zh) * 2014-03-26 2014-06-25 邵娜 一种黄体酮口腔崩解片及其制备方法
WO2015160595A1 (en) * 2014-04-14 2015-10-22 Abbott Molecular, Inc. Medium used for blood sample collection and transport
CA2988495C (en) 2015-06-18 2022-02-08 Mithra Pharmaceuticals S.A. Orodispersible dosage unit containing an estetrol component
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
CU24523B1 (es) 2015-06-18 2021-06-08 Estetra Sprl Unidad de dosificación orodispersable que contiene un componente estetrol
EP3310345B1 (en) 2015-06-18 2021-03-31 Estetra SPRL Orodispersible tablet containing estetrol
WO2018010543A1 (zh) * 2016-07-11 2018-01-18 武汉朗来科技发展有限公司 一种用于口服固体制剂的复合崩解剂体系及含有该复合崩解剂体系的口服固体制剂
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
CN109276550B (zh) * 2018-11-27 2021-01-12 西安圣雪沙药物开发有限公司 一种左炔诺孕酮片及其制备方法
CN110917154A (zh) * 2019-12-12 2020-03-27 上海信谊天平药业有限公司 一种左炔诺孕酮片的制备方法
WO2022225986A1 (en) * 2021-04-19 2022-10-27 Archer David Fitzgerald On demand female contraceptive

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK174724B1 (da) * 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
US5633011A (en) 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
GB9603699D0 (en) * 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
EP0904084A4 (en) 1996-05-16 2001-02-07 Gynetics Inc EMERGENCY CONCEPT PREVENTION KIT
JPH1171268A (ja) * 1997-08-28 1999-03-16 Kayaku:Kk 性ホルモン含有錠剤
FR2772617B1 (fr) 1997-12-19 2001-03-09 Besins Iscovesco Lab Comprime de progesterone et son procede de preparation
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
WO2000054752A1 (fr) * 1999-03-15 2000-09-21 Kaken Pharmaceutical Co., Ltd. Comprimes a delitement rapide et procede de fabrication
US6667050B1 (en) 1999-04-06 2003-12-23 Galen (Chemicals) Limited Chewable oral contraceptive
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
ME00145B (me) * 2001-01-26 2010-10-10 Merck Sharp & Dohme Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
HU227198B1 (en) * 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
US6962908B2 (en) * 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
US7749533B2 (en) * 2003-05-07 2010-07-06 Akina, Inc. Highly plastic granules for making fast melting tablets
KR101159617B1 (ko) * 2003-10-15 2012-06-27 후지카가쿠고교가부시키가이샤 구강내 속붕해성 정제
JP4519444B2 (ja) * 2003-10-31 2010-08-04 ライオン株式会社 口腔内崩壊錠
EP1691746B1 (en) * 2003-12-08 2015-05-27 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
CN1634077A (zh) * 2004-11-18 2005-07-06 王立强 左炔诺孕酮口腔崩解片制剂及其制备方法
WO2006115770A2 (en) * 2005-04-22 2006-11-02 Teva Pharmaceuticals Usa, Inc. Orally disintegrating pharmaceutical tablet formulations of olanzapine
EA015155B1 (ru) 2005-05-26 2011-06-30 Тева Вуменс Хелс, Инк. Дозированные формы для перорального применения, содержащие прогестерон, и способы их изготовления и использования
ES2531929T3 (es) * 2006-12-20 2015-03-20 Teva Women's Health, Inc. Formas de dosificación solidas que se disgregan en la boca que comprenden progestina y métodos para hacer y usar las mismas
AU2008341138A1 (en) 2007-12-20 2009-07-02 Teva Women's Health, Inc. Dosage regimens and pharmaceutical compositions and packages for emergency contraception

Also Published As

Publication number Publication date
EP2124900A2 (en) 2009-12-02
WO2008079245A2 (en) 2008-07-03
JP2010513514A (ja) 2010-04-30
US20110136771A1 (en) 2011-06-09
RU2465907C2 (ru) 2012-11-10
JP5649305B2 (ja) 2015-01-07
EP2124900B1 (en) 2014-12-03
CA2674776A1 (en) 2008-07-03
AU2007338843A1 (en) 2008-07-03
US7867515B2 (en) 2011-01-11
WO2008079245A3 (en) 2008-12-04
RU2009125972A (ru) 2011-01-27
US8226980B2 (en) 2012-07-24
AU2007338843B2 (en) 2013-05-09
BRPI0719486A2 (pt) 2014-02-18
EP2124900A4 (en) 2013-04-03
ES2531929T3 (es) 2015-03-20
IL199472A0 (en) 2010-03-28
US20080175906A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
MX2009006823A (es) Formas de dosificacion solidas de desintegracion oral que comprenden progestina y metodos para hacer y usar las mismas.
MX2009009428A (es) Analogos de ciclopamina heterociclicos y metodos de uso de los mismos.
EP4275752A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
MX2020004099A (es) Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
HK1139930A1 (en) Cyclopamine lactam analogs and methods of use thereof
MX350761B (es) Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa.
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
UA103915C2 (ru) Твердая лекарственная форма, которая содержит линаглиптин и ингибитор sglt2, и ее применение
TNSN08283A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
EP1962839A4 (en) ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
WO2010068794A3 (en) Hif inhibitors and use thereof
MX2011011109A (es) Formulaciones orales de bendamustina.
IN2012DN02471A (es)
TW200738669A (en) Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
NO20092143L (no) Anvendelse av testosteron og en 5-HT1A-agonist ved behandling av seksuell dysfunksjon
EP2328550A4 (en) MUCOADHERENT COMPOSITIONS AND THEIR USE
WO2008052139A3 (en) Ultra low dose doxepin and methods of using the same to treat sleep disorders
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration